Covaxin, the coronavirus vaccine candidate developed by Hyderabad-based Bharat Biotech, induces an immune response and registered no serious adverse events, the company said Wednesday evening as it released results of Phase I trials.
The vaccine “induced (a) neutralising antibody (an immune response)” and was “well-tolerated in all dose groups with no vaccine-related serious adverse events”, the company said.
“After the first vaccination, local and systemic adverse events were predominantly mild or moderate in severity and resolved rapidly, without any prescribed medication. The most common adverse event was pain at the injection site, which resolved spontaneously,” it added.
Covaxin is one of three vaccine candidates that has applied to the centre for emergency use authorisation.